Answers are grounded in this paper and cite their sources.
Postoperative pain management following bariatric surgery remains challenging, and conventional opioid-based analgesic regimens are associated with a range of adverse effects. We therefore evaluated whether an esketamine-containing reduced-opioid PCA regimen could improve analgesic efficacy during the initial 72 h after laparoscopic sleeve gastrectomy. In this single-center randomized controlled trial, 119 patients were randomly assigned 1:1 to either the esketamine group (EG) or the sufentanil group (SG), with block sizes of 2 or 4 and stratification by BMI. One patient in the SG was excluded after randomization because the planned laparoscopic sleeve gastrectomy was not performed, leaving 118 patients (EG 59, SG 59) in the modified intention-to-treat analysis. Group-based patient-controlled analgesia (PCA) was administered: EG received esketamine 1 mg/kg plus sufentanil 1 µg/kg, and sufentanil 2.5 µg/kg was used in SG. The primary outcome was postoperative pain intensity over 72 h assessed by the Numeric Rating Scale (NRS). Secondary outcomes included opioid consumption, postoperative nausea and vomiting (PONV), sleep quality, recovery indicators, and adverse events. Compared with the sufentanil group (SG), the esketamine group (EG) exhibited significantly lower dynamic pain scores over the 72-hour period (group effect: ATS = 12.59, df = 1.00, P < 0.001), whereas no significant overall group effect was observed for resting pain (ATS = 1.97, df = 1.00, P = 0.160). Regarding secondary outcomes, the EG was associated with lower postoperative sufentanil exposure and better sleep quality ( P < 0.001). Safety profiles were comparable between groups, except for a higher incidence of diaphoresis in the EG (23.7% vs. 5.1%; OR = 5.807; 95% CI, 1.571–21.464; P = 0.004). An esketamine–sufentanil, reduced-opioid PCA regimen, compared with a sufentanil PCA regimen, provided effective postoperative pain control after laparoscopic sleeve gastrectomy and was associated with lower early PONV. This prospective, randomized, double-blind clinical trial was registered with the Chinese Clinical Trial Registry on April 27, 2025 (ChiCTR2500101603).
No takes yet. Share an insight, caveat, or question.
Shi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: